The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.

Condition	Treatment or Intervention	Phase
Cardiovascular Disease Coronary Artery Bypass Surgery	Drug: Angiomax (bivalirudin)	Phase III

Further Study Details: 

Expected Total Enrollment:  150

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

• Provide written informed consent before initiation of any study related procedures.
• Be at least 18 years of age.
• Be scheduled for CABG, CABG and single valve surgery, or isolated single valve surgery on CPB. Patients undergoing repeat (redo) CABG are also considered eligible for this study.

Exclusion Criteria

• Confirmed pregnancy at time of randomization via IVRS (if woman of child-bearing potential) (Urine or serum pregnancy test)
• Cerebrovascular accident within 6 months, or any cerebrovascular accident with a residual neurological deficit.
• Intracranial neoplasm, arteriovenous malformation or aneurysm.
• Dependency on renal dialysis or creatinine clearance <30 mL/min.
• Ongoing treatment with warfarin (or other oral anticoagulant) at the time of randomization. Patients previously treated with warfarin may be enrolled if warfarin therapy can be safely discontinued and baseline INR is < 1.3 times control in the absence of heparin therapy.
• Known allergy to Angiomax or hirudin-derived drugs, or known sensitivity to any component of the product.
• Patients receiving clopidogrel (Plavix®) within the previous 5 days of randomization
• Patients receiving a glycoprotein IIb/IIIa inhibitor within the previous 48 hours if abciximab (ReoPro®) or 24 hours if eptifibatide (Integrilin®) or tirofiban (Aggrastat®) of randomization.
• Patients receiving lepirudin (Refludan®) or argatroban within the previous 24 hours prior to randomization.
• Patients receiving LMWH or thrombolytics within the previous 12 hours or unfractionated heparin within 30 minutes of randomization.
• Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization.
• Refusal to undergo blood transfusion should it become necessary.
• Any other disease or condition, which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial.
• Planned surgical procedure in which proximal anastomoses will precede distal anastomoses of the bypass grafts.
• Planned (>1) double (or greater) valve repair-replacement (e.g.: AVR-MVR) surgery.

Linda Rootkin, BSc      973-647-6093    linda.rootkin@themedco.com
Katey Fox, RN      973-647-6076    katey.fox@themedco.com

Ohio
      The Cleveland Clinic, Cleveland,  Ohio,  44195,  United States; Recruiting

Study chairs or principal investigators

Malcolm Lloyd, MD,  Study Director,  The Medicines Company   

Study ID Numbers:  TMC-BIV-02-06; EVOLUTION-On
Record last reviewed:  October 2004
Last Updated:  October 13, 2004
Record first received:  March 9, 2004
ClinicalTrials.gov Identifier:  NCT00079586
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08